Advanced Therapies Europe 2022

  The Advanced Therapies Europe 2022 conference focused on exploring the commercialization of advanced therapy medicinal products (ATMPs), with talks on patient access, the manufacturing chain, and clinical case studies of cell and gene therapies. The event targeted Europeans looking for global growth as well as the global audience aiming to expand into the European […]

Advanced Therapies Congress, 24-25 May, 2022, ExCel, London

On the 24th of May, 2022, PMM team members, Xuanqi Song and Sam Jarada, attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes to the development of patient access to advanced therapy medicinal products (ATMP). […]

What is CAR-T cell therapy?

Seema Bachoo   Immunotherapy is a type of cancer treatment that makes use of a patient’s own immune system to target and destroy cancer cells, with the aim of eliminating cancer from the body. There are several different types of immunotherapies. Cytokine-based immunotherapies harness the power of cytokines, which are soluble proteins that stimulate and […]

How immunotherapy can improve colorectal cancer prognosis

Aaron Logsdon   Abbreviations CAR, chimeric antigen receptor; CAR-T, chimeric antigen receptor T lymphocyte therapy; CRC, colorectal cancer; DCR, disease control rate; dMMR, mismatch repair-deficient; FDA, US Food and Drug Administration; ICI, immune checkpoint inhibition; MMR, mismatch repair genes; MSI-H, high microsatellite instability; MSS, microsatellite stable; OR, objective response; pMMR, mismatch repair proficient; Treg, T […]

Advanced Therapies Congress & Expo 2021

On the 5th of October, 2021, PMM team members Celeste Cohen, Shannon Hylton, and Aaron Logsdon attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes to the development of patient access to advanced therapy medicinal products […]